company background image
455 logo

Tianda Pharmaceuticals SEHK:455 Stock Report

Last Price

HK$0.23

Market Cap

HK$494.5m

7D

-5.0%

1Y

15.0%

Updated

01 Jun, 2024

Data

Company Financials

Tianda Pharmaceuticals Limited

SEHK:455 Stock Report

Market Cap: HK$494.5m

455 Stock Overview

Engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia.

455 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Tianda Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tianda Pharmaceuticals
Historical stock prices
Current Share PriceHK$0.23
52 Week HighHK$0.28
52 Week LowHK$0.18
Beta0.12
1 Month Change-14.81%
3 Month Change-11.54%
1 Year Change15.00%
3 Year Change1.32%
5 Year Change0%
Change since IPO-60.68%

Recent News & Updates

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27
There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Recent updates

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27
There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Mar 02
Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

May 23
Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

Dec 06
Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Jan 11
Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Aug 05
Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

Dec 11
Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

Shareholder Returns

455HK PharmaceuticalsHK Market
7D-5.0%-0.6%-2.3%
1Y15.0%-7.0%0.3%

Return vs Industry: 455 exceeded the Hong Kong Pharmaceuticals industry which returned -7% over the past year.

Return vs Market: 455 exceeded the Hong Kong Market which returned 0.3% over the past year.

Price Volatility

Is 455's price volatile compared to industry and market?
455 volatility
455 Average Weekly Movement7.0%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement7.3%
10% most volatile stocks in HK Market15.7%
10% least volatile stocks in HK Market3.8%

Stable Share Price: 455 has not had significant price volatility in the past 3 months.

Volatility Over Time: 455's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992863Alan Fangwww.tiandapharma.com

Tianda Pharmaceuticals Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. It provides Chinese medicines, chemical drugs, biological and health products, and medical appliances covering therapy areas of cardio-cerebrovascular, pediatric, anti-flu and respiratory, anti-infection, detoxification, anti-cancer, and others. The company offers its health products under the Herb Valley and Tuokang brands.

Tianda Pharmaceuticals Limited Fundamentals Summary

How do Tianda Pharmaceuticals's earnings and revenue compare to its market cap?
455 fundamental statistics
Market capHK$494.51m
Earnings (TTM)-HK$24.15m
Revenue (TTM)HK$532.09m

0.9x

P/S Ratio

-20.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
455 income statement (TTM)
RevenueHK$532.09m
Cost of RevenueHK$276.56m
Gross ProfitHK$255.53m
Other ExpensesHK$279.69m
Earnings-HK$24.15m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.011
Gross Margin48.02%
Net Profit Margin-4.54%
Debt/Equity Ratio17.7%

How did 455 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

-23%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.